Medicine
Xipere 36 mg/0.9 mL injectable suspension
Xipere 36 mg/0.9 mL injectable suspension is a prescription medicine containing Triamcinolone acetonide for ophthalmic use, marketed by Bausch & Lomb, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 15°C to 25°C (59°F to 77°F), do not freeze. The drug vial should be…
Key facts
- Active ingredient (INN)
- Triamcinolone acetonide
- Brand
- Xipere
- Strength
- 36 mg/0.9 mL
- Dosage form
- Injectable suspension
- Route
- Ophthalmic
- Packs
- 1 tray of 0.9 mL
- Marketing authorisation holder
- Bausch & Lomb
- Manufacturer
- Bausch & Lomb
- Origin register
- US FDA, United States
- Storage
- Store at 15°C to 25°C (59°F to 77°F), do not freeze. The drug vial should be protected from light by storing in the carton.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.32Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 December 2021
- Identifiers
- RxCUI 2585221, 2585226DailyMed set ID ea6ad429-967f-4f75-a33d-e06f849bee80NDC 24208-040Application NDA211950
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 tray in 1 carton / 1 vial in 1 tray / .9 mL in 1 vial | 24208-040-40 | Bausch & Lomb | 17 December 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 23 October 1958 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Triamcinolone acetonide
Clinical summary
Triamcinolone acetonide is a corticosteroid indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis. MedsAcross supplies Triamcinolone acetonide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Triamcinolone acetonideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- KENALOG-10 prescribing information (ER Squibb & Sons) · U.S. National Library of Medicine, DailyMed
Need Xipere 36 mg/0.9 mL injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.